PBAC's latest decision on Enoxaparin sodium: Recommended (2020). Considered for Prevention of thromboembolic disorders and treatment of established thrombotic conditions, including prevention in orthopaedic and general surgery, prophylaxis in bedridden medical patients, prevention in haemodialysis, treatment of deep vein thrombosis, treatment of unstable angina and non-Q-wave myocardial infarction, and treatment of acute STEMI.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2014
Submissions
2
2014 → 2020
Eligible population
Patients requiring enoxaparin for prevention of thromboembolic disorders in orthopaedic and general surgery, prophylaxis in bedridden medical patients with acute illness, prevention of thrombosis in haemodialysis, treatment of established deep vein thrombosis, treatment of unstable angina and non-Q-wave myocardial infarction, and treatment of acute STEMI.
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Clexane Safety-Lock
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
Submission history
Nov 2014: Recommended with restriction · Restricted